195 results on '"Tewari, Krishnansu S."'
Search Results
2. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Birrer, Michael J, Penson, Richard T, Huang, Helen, Moore, David H, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, Monk, Bradley J, Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Birrer, Michael J, Penson, Richard T, Huang, Helen, Moore, David H, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, and Monk, Bradley J
- Abstract
ObjectiveTo determine whether a non‑platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma.MethodsGynecologic Oncology Group protocol 240 is a phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxel 175 mg/m2 plus topotecan 0.75 mg/m2 days 1-3 (n = 223) vs cisplatin 50 mg/m2 plus paclitaxel 135 or 175 mg/m2 (n = 229), in 452 patients with recurrent/metastatic cervical cancer. Each chemotherapy doublet was also studied with and without bevacizumab (15 mg/kg). Cycles were repeated every 21 days until progression, unacceptable toxicity, or complete response. The primary endpoints were OS and the frequency and severity of adverse effects. We report the final analysis of OS.ResultsAt the protocol-specified final analysis, median OS was 16.3 (cisplatin-paclitaxel backbone) and 13.8 months (topotecan-paclitaxel backbone) (HR 1.12; 95% CI, 0.91-1.38; p = 0.28). Median OS for cisplatin-paclitaxel and topotecan-paclitaxel was 15 vs 12 months, respectively (HR 1.10; 95% CI,0.82-1.48; p = 0.52), and for cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab was 17.5 vs 16.2 months, respectively (HR 1.16; 95% CI, 0.86-1.56; p = 0.34). Among the 75% of patients in the study population previously exposed to platinum, median OS was 14.6 (cisplatin-paclitaxel backbone) vs 12.9 months (topotecan-paclitaxel backbone), respectively (HR 1.09; 95% CI, 0.86-1.38;p = 0.48). Post-progression survival was 7.9 (cisplatin-paclitaxel backbone) vs 8.1 months (topotecan-paclitaxel backbone) (HR 0.95; 95% CI, 0.75-1.19). Grade 4 hematologic toxicity was similar between chemotherapy backbones.ConclusionsTopotecan plus paclitaxel does not confer a survival benefit to women with recurrent/metastatic cervical cancer, even among platinum-exposed patients. Topotecan-paclitaxel should not be routinely recommended in this population. NCT00803062.
- Published
- 2023
3. Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer:Results from the innovaTV 205/GOG-3024/ENGOT-cx8 Study
- Author
-
Vergote, Ignace, Van Nieuwenhuysen, Els, O'Cearbhaill, Roisin E., Westermann, Anneke, Lorusso, Domenica, Ghamande, Sharad, Collins, Dearbhaile C., Banerjee, Susana, Mathews, Cara A., Gennigens, Christine, Cibula, David, Tewari, Krishnansu S., Madsen, Kristine, Köse, Fatih, Jackson, Amanda L., Boere, Ingrid A., Scambia, Giovanni, Randall, Leslie M., Sadozye, Azmat, Baurain, Jean François, Gort, Eelke, Zikán, Michal, Denys, Hannelore G., Ottevanger, Nelleke, Forget, Frédéric, Mondrup Andreassen, Camilla, Eaton, Lamar, Chisamore, Michael J., Viana Nicacio, Leonardo, Soumaoro, Ibrahima, Monk, Bradley J., Vergote, Ignace, Van Nieuwenhuysen, Els, O'Cearbhaill, Roisin E., Westermann, Anneke, Lorusso, Domenica, Ghamande, Sharad, Collins, Dearbhaile C., Banerjee, Susana, Mathews, Cara A., Gennigens, Christine, Cibula, David, Tewari, Krishnansu S., Madsen, Kristine, Köse, Fatih, Jackson, Amanda L., Boere, Ingrid A., Scambia, Giovanni, Randall, Leslie M., Sadozye, Azmat, Baurain, Jean François, Gort, Eelke, Zikán, Michal, Denys, Hannelore G., Ottevanger, Nelleke, Forget, Frédéric, Mondrup Andreassen, Camilla, Eaton, Lamar, Chisamore, Michael J., Viana Nicacio, Leonardo, Soumaoro, Ibrahima, and Monk, Bradley J.
- Abstract
PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E).CONCLUSION TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.
- Published
- 2023
4. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Monk, Bradley J, Tewari, Krishnansu S, Dubot, Coraline, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Hurtado de Mendoza, Mivael Olivera, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Martin Nguyen, Allison, Monberg, Matthew J, Colombo, Nicoletta, Lorusso, Domenica, Monk, Bradley J, Tewari, Krishnansu S, Dubot, Coraline, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Hurtado de Mendoza, Mivael Olivera, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Martin Nguyen, Allison, Monberg, Matthew J, Colombo, Nicoletta, and Lorusso, Domenica
- Abstract
Background: In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus chemotherapy with or without bevacizumab, with manageable toxicity, in patients with persistent, recurrent, or metastatic cervical cancer. In this Article, we report patient-reported outcomes (PROs) from KEYNOTE-826. Methods: KEYNOTE-826 is a multicentre, randomised, phase 3 trial in 151 cancer treatment centres in 19 countries. Eligible patients were aged 18 years or older with persistent, recurrent, or metastatic cervical cancer not previously treated with systemic chemotherapy (previous radiosensitising chemotherapy was allowed) and not amenable to curative treatment and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either pembrolizumab 200 mg or placebo every 3 weeks intravenously for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin area under the curve 5 mg/mL per min, intravenously) with or without bevacizumab 15 mg/kg every 3 weeks intravenously. Randomisation (block size of 4) was stratified by metastatic disease at diagnosis, planned bevacizumab use, and PD-L1 combined positive score. Patients, investigators, and other study personnel involved in study treatment administration or clinical evaluation of patients were unaware of treatment group assignments. PRO instruments were the EORTC Quality-of-Life-Core 30 (QLQ-C30), the EORTC cervical cancer module (QLQ-CX24), and the EuroQol-5 dimension-5 level (EQ-5D-5L) visual analogue scale, each collected before treatment at cycles 1-14 and every other cycle thereafter. Primary endpoints were overall survival and progression-free survival per RECIST version 1.1 by investigator
- Published
- 2023
5. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Monk, B, Tewari, K, Dubot, C, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yañez, E, Gümüş, M, Hurtado de Mendoza, M, Samouëlian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Martin Nguyen, A, Monberg, M, Colombo, N, Lorusso, D, Monk, Bradley J, Tewari, Krishnansu S, Dubot, Coraline, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Hurtado de Mendoza, Mivael Olivera, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Martin Nguyen, Allison, Monberg, Matthew J, Colombo, Nicoletta, Lorusso, Domenica, Monk, B, Tewari, K, Dubot, C, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yañez, E, Gümüş, M, Hurtado de Mendoza, M, Samouëlian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Martin Nguyen, A, Monberg, M, Colombo, N, Lorusso, D, Monk, Bradley J, Tewari, Krishnansu S, Dubot, Coraline, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Hurtado de Mendoza, Mivael Olivera, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Martin Nguyen, Allison, Monberg, Matthew J, Colombo, Nicoletta, and Lorusso, Domenica
- Abstract
Background: In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus chemotherapy with or without bevacizumab, with manageable toxicity, in patients with persistent, recurrent, or metastatic cervical cancer. In this Article, we report patient-reported outcomes (PROs) from KEYNOTE-826. Methods: KEYNOTE-826 is a multicentre, randomised, phase 3 trial in 151 cancer treatment centres in 19 countries. Eligible patients were aged 18 years or older with persistent, recurrent, or metastatic cervical cancer not previously treated with systemic chemotherapy (previous radiosensitising chemotherapy was allowed) and not amenable to curative treatment and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either pembrolizumab 200 mg or placebo every 3 weeks intravenously for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin area under the curve 5 mg/mL per min, intravenously) with or without bevacizumab 15 mg/kg every 3 weeks intravenously. Randomisation (block size of 4) was stratified by metastatic disease at diagnosis, planned bevacizumab use, and PD-L1 combined positive score. Patients, investigators, and other study personnel involved in study treatment administration or clinical evaluation of patients were unaware of treatment group assignments. PRO instruments were the EORTC Quality-of-Life-Core 30 (QLQ-C30), the EORTC cervical cancer module (QLQ-CX24), and the EuroQol-5 dimension-5 level (EQ-5D-5L) visual analogue scale, each collected before treatment at cycles 1–14 and every other cycle thereafter. Primary endpoints were overall survival and progression-free survival per RECIST version 1.1 by investigator
- Published
- 2023
6. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Monk, Bradley J, Penson, Richard T, Moore, David H, Lankes, Heather A, Ramondetta, Lois M, Landrum, Lisa M, Randall, Leslie M, Oaknin, Ana, Leitao, Mario M, Eisenhauer, Eric L, DiSilvestro, Paul, Van Le, Linda, Pearl, Michael L, Burke, James J, Salani, Ritu, Richardson, Debra L, Michael, Helen E, Kindelberger, David W, Birrer, Michael J, Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Monk, Bradley J, Penson, Richard T, Moore, David H, Lankes, Heather A, Ramondetta, Lois M, Landrum, Lisa M, Randall, Leslie M, Oaknin, Ana, Leitao, Mario M, Eisenhauer, Eric L, DiSilvestro, Paul, Van Le, Linda, Pearl, Michael L, Burke, James J, Salani, Ritu, Richardson, Debra L, Michael, Helen E, Kindelberger, David W, and Birrer, Michael J
- Abstract
To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1 and 36 days post-cycle 1 from patients enrolled on Gynecologic Oncology Group 0240, the phase III randomized trial that led directly to regulatory approval of the antiangiogenesis drug, bevacizumab, in women with recurrent/metastatic cervical cancer. CTCs (defined as anti-cytokeratin+/anti-CD45- cells) were isolated from the buffy coat layer using an anti-EpCAM antibody-conjugated ferrofluid and rare earth magnet, and counted using a semiautomated fluorescence microscope. The median pre-cycle 1 CTC count was 7 CTCs/7.5 mL whole blood (range, 0-18) and, at 36 days posttreatment, was 4 (range, 0-17). The greater the declination in CTCs between time points studied, the lower the risk of death [HR, 0.87; 95% confidence interval (CI), 0.79-0.95)]. Among patients with high (≥ median) pretreatment CTCs, bevacizumab treatment was associated with a reduction in the hazard of death (HR, 0.57; 95% CI, 0.32-1.03) and PFS (HR, 0.59; 95% CI, 0.36-0.96). This effect was not observed with low (< median) CTCs. CTCs can be isolated from women with advanced cervical cancer and may have prognostic significance. A survival benefit conferred by bevacizumab among patients with high pretreatment CTCs may reflect increased tumor neovascularization and concomitant vulnerability to VEGF inhibition. These data support studying CTC capture as a potential predictive biomarker.
- Published
- 2020
7. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Coleman, Robert L, Aghajanian, Carol, Mannel, Robert, DiSilvestro, Paul A, Powell, Matthew, Randall, Leslie M, Farley, John, Rubin, Stephen C, Monk, Bradley J, Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Coleman, Robert L, Aghajanian, Carol, Mannel, Robert, DiSilvestro, Paul A, Powell, Matthew, Randall, Leslie M, Farley, John, Rubin, Stephen C, and Monk, Bradley J
- Abstract
ObjectiveTo explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin.MethodsAn exploratory, post-hoc analysis of the randomized phase II trial, Gynecologic Oncology Group-0186I, was performed. One hundred and seven patients with recurrent ovarian carcinoma, treated with up to 3 prior regimens, were randomized to bevacizumab 15 mg/kg body weight with or without intravenous fosbretabulin 60 mg/m2 body surface area every 21 days until progression or unacceptable toxicity. The primary analysis favored the combination (HR 0.69; 95% CI, 0.47-1.00; p = .049) [Monk BJ, et al. J Clin Oncol 2016;34:2279-86]. The Cox proportional hazards model was used to estimate the treatment effect in various subpopulations.ResultsWith extended follow-up, the median PFS for bevacizumab plus fosbretabulin was 7.6 months as compared to 4.8 months with bevacizumab alone (HR 0.74; 90% CI, 0.54-1.02). Overall survival was similar in the experimental and control arms (25.2 vs 24.4 mos, respectively, HR 0.85; 90% CI, 0.59-1.22; p = .461). Eighty-one patients had measurable disease and median tumor size was 5.7 cm. In the ≤5.7 cm subgroup, the HR for progression or death was 0.77 (90% CI 0.45-1.31). Patients with tumors >5.7 cm (n = 40) had a HR for progression or death of 0.55; 90% CI, 0.32-0.96; p = .075).ConclusionsAlthough no significant survival benefit was observed, the trend showing a reduced HR for progression or death with increasing tumor size when fosbretabulin is added to bevacizumab compared to bevacizumab alone warrants further study.
- Published
- 2020
8. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
- Author
-
Aghajanian, Carol, Aghajanian, Carol, Swisher, Elizabeth M, Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A, Fleming, Gini F, Friedlander, Michael, Moore, Kathleen N, Tewari, Krishnansu S, O'Malley, David M, Chan, John K, Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H, Coleman, Robert L, Aghajanian, Carol, Aghajanian, Carol, Swisher, Elizabeth M, Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A, Fleming, Gini F, Friedlander, Michael, Moore, Kathleen N, Tewari, Krishnansu S, O'Malley, David M, Chan, John K, Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H, and Coleman, Robert L
- Abstract
ObjectiveIn the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus chemotherapy alone. Here we present exploratory analyses by paclitaxel dosing schedule and germline BRCA (gBRCA) status.MethodsWomen with untreated ovarian carcinoma were randomized (1:1:1) to: veliparib during chemotherapy and maintenance (veliparib-throughout), veliparib during chemotherapy followed by placebo maintenance (veliparib-combination only), or placebo during chemotherapy and maintenance (control). Chemotherapy included carboplatin plus dose-dense (DD; weekly) or every-3-week (Q3W) paclitaxel (a stratification factor at randomization), selected at the investigator's discretion pre-randomization. PFS was assessed by paclitaxel dosing schedule using a Cox proportional hazard model adjusted by treatment arm and stratification factors; safety was analyzed based on paclitaxel dosing schedule and gBRCA status.Results1132 patients were analyzed by paclitaxel schedule. Pooled treatment arms demonstrated longer median PFS with DD (n = 586) versus Q3W (n = 546) paclitaxel (ITT: 20.5 vs 15.7 months, hazard ratio [HR] 0.77; homologous recombination proficient cancer: 15.1 vs 11.8 months, HR 0.64; BRCAwt: 18.0 vs 12.9 months, HR 0.70). Comparison between arms favored veliparib-throughout versus control in both DD (PFS, 24.2 vs 18.3 months, hazard ratio 0.67) and Q3W (19.3 vs 14.6, hazard ratio 0.69) subgroups. DD paclitaxel was associated with higher incidence of Grade 3/4 neutropenia, fatigue, and anemia versus Q3W. There were no differences in toxicity between gBRCAm (n = 211) and gBRCAwt (n = 902) subgroups.ConclusionsDD paclitaxel was tolerable and associated with longer PFS in the HR proficient and gBRCAwt groups, versus Q3W. gBRCA status did not impact safety
- Published
- 2022
9. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.
- Author
-
Chan, John K, Chan, John K, Tian, Chunqiao, Kesterson, Joshua P, Monk, Bradley J, Kapp, Daniel S, Davidson, Brittany, Robertson, Sharon, Copeland, Larry J, Walker, Joan L, Wenham, Robert M, Casablanca, Yovanni, Spirtos, Nick M, Tewari, Krishnansu S, Bell, Jeffrey G, Chan, John K, Chan, John K, Tian, Chunqiao, Kesterson, Joshua P, Monk, Bradley J, Kapp, Daniel S, Davidson, Brittany, Robertson, Sharon, Copeland, Larry J, Walker, Joan L, Wenham, Robert M, Casablanca, Yovanni, Spirtos, Nick M, Tewari, Krishnansu S, and Bell, Jeffrey G
- Abstract
ObjectiveTo assess the presentation, characteristics, and prognostic significance of symptoms in patients with high-risk early-stage epithelial ovarian cancer.MethodsA retrospective chart review was performed on all patients enrolled in a phase III clinical trial (GOG 157). All patients had surgically staged, high-risk early-stage epithelial ovarian cancer (stage IA-IB and grade 3, any clear cell, stage IC or II). Chi-square and Kaplan-Meier estimates and Cox proportional hazards models were used for statistical analyses.ResultsOf 419 patients evaluated for symptoms, 301 (72%) presented with one or more symptoms, and 118 (28%) were asymptomatic but had a mass found on examination. Forty percent had only one symptom, and 32% had more than one symptom. Among those with at least one symptom, the most common were abdominal and pelvic pain (31%), and increased girth or fullness (26%). Overall, 23% of patients with tumors 10 cm or smaller, 27% of patients with tumors larger than 10 cm to 15 cm, and 46% of patients with tumors larger than 15 cm had multiple symptoms (P<.001). There was no significant difference in presentation of symptoms based on age, stage, or histologic subtype. Symptoms at diagnosis were not associated with recurrence or survival.ConclusionMore than 70% of patients with high-risk early-stage, epithelial ovarian cancer present with one or more symptoms, with the most common being abdominal or pelvic pain. The proportion of women with symptoms and the number of symptoms increase with enlarging tumor size.
- Published
- 2022
10. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
- Author
-
You, Benoit, You, Benoit, Purdy, Christopher, Copeland, Larry J, Swisher, Elizabeth M, Bookman, Michael A, Fleming, Gini, Coleman, Robert, Randall, Leslie M, Tewari, Krishnansu S, Monk, Bradley J, Mannel, Robert S, Walker, Joan L, Cappuccini, Fabio, Cohn, David, Muzaffar, Mahvish, Mutch, David, Wahner-Hendrickson, Andrea, Martin, Lainie, Colomban, Olivier, Burger, Robert A, You, Benoit, You, Benoit, Purdy, Christopher, Copeland, Larry J, Swisher, Elizabeth M, Bookman, Michael A, Fleming, Gini, Coleman, Robert, Randall, Leslie M, Tewari, Krishnansu S, Monk, Bradley J, Mannel, Robert S, Walker, Joan L, Cappuccini, Fabio, Cohn, David, Muzaffar, Mahvish, Mutch, David, Wahner-Hendrickson, Andrea, Martin, Lainie, Colomban, Olivier, and Burger, Robert A
- Abstract
PurposeIn patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMination rate constant K [KELIM] score) was a predictive biomarker. Only the patients with high-risk disease (suboptimally resected stage III, or stage IV) exhibiting unfavorable KELIM score < 1.0 had overall survival (OS) benefit from bevacizumab (median: 29.7 v 20.6 months; hazard ratio [HR], 0.78). An external validation study in the GOG-0218 trial was performed.MethodsIn GOG-0218, 1,873 patients were treated with carboplatin-paclitaxel ± concurrent-maintenance bevacizumab/placebo. Patient KELIM values were calculated with CA-125 kinetics during the first 100 chemotherapy days by the Lyon University team. The association between KELIM score (favorable ≥ 1.0, or unfavorable < 1.0) and bevacizumab benefit for progression-free survival (PFS)/OS was independently assessed by NGR-GOG using univariate/multivariate analyses.ResultsKELIM was assessable in 1,662 patients with ≥ 3 CA-125 available values. An unfavorable KELIM score was associated with bevacizumab benefit compared with placebo (PFS: HR, 0.70; 95% CI, 0.59 to 0.82; OS: HR, 0.87; 95% CI, 0.73 to 1.03), whereas a favorable KELIM was not (PFS: HR, 0.96; 95% CI, 0.79 to 1.17; OS: HR, 1.11; 95% CI, 0.89 to 1.39). The highest benefit was observed in patients with a high-risk disease exhibiting unfavorable KELIM, for PFS (median: 9.1 v 5.6 months; HR, 0.64; 95% CI, 0.53 to 0.78), and for OS (median: 35.1 v 29.1 months; HR, 0.79; 95% CI, 0.65 to 0.97).ConclusionThis GOG-0218 trial investigation validates ICON-7 findings about the association between poor tumor chemosensitivity and benefit from concurrent-maintenance bevacizumab, suggesting that bevacizumab may mainly be effective in patients with poorly chemosensitive disease. Bevacizumab may be prioritized in patients w
- Published
- 2022
11. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
- Author
-
Pitiyarachchi, Omali, Pitiyarachchi, Omali, Friedlander, Michael, Java, James J, Chan, John K, Armstrong, Deborah K, Markman, Maurie, Herzog, Thomas J, Monk, Bradley J, Backes, Floor, Secord, Angeles Alvarez, Bonebrake, Albert, Rose, Peter G, Tewari, Krishnansu S, Lentz, Samuel S, Geller, Melissa A, Copeland, Larry J, Mannel, Robert S, Pitiyarachchi, Omali, Pitiyarachchi, Omali, Friedlander, Michael, Java, James J, Chan, John K, Armstrong, Deborah K, Markman, Maurie, Herzog, Thomas J, Monk, Bradley J, Backes, Floor, Secord, Angeles Alvarez, Bonebrake, Albert, Rose, Peter G, Tewari, Krishnansu S, Lentz, Samuel S, Geller, Melissa A, Copeland, Larry J, and Mannel, Robert S
- Abstract
ObjectivePatients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS.MethodsData from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS.ResultsOf 1174 patients randomized, 10-year overall survival (OS) was 26% (95% CI, 23-28%) and LTDFS ≥10 years was 18% (95% CI, 16-20%). Patients with LTDFS ≥10 years had a median age of 54.6 years (p < 0.001). Younger age (p < 0.001) was the only independent prognostic factor for LTDFS≥10 years on multivariate Cox analysis.ConclusionsApproximately 18% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes.
- Published
- 2022
12. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
- Author
-
Matulonis, Ursula A, Matulonis, Ursula A, Huang, Helen Q, Filiaci, Virginia L, Randall, Marcus, DiSilvestro, Paul A, Moxley, Katherine M, Fowler, Jeffrey M, Powell, Matthew A, Spirtos, Nick M, Tewari, Krishnansu S, Richards, William E, Nakayama, John M, Mutch, David G, Miller, David S, Matei, Daniela, Wenzel, Lari B, Matulonis, Ursula A, Matulonis, Ursula A, Huang, Helen Q, Filiaci, Virginia L, Randall, Marcus, DiSilvestro, Paul A, Moxley, Katherine M, Fowler, Jeffrey M, Powell, Matthew A, Spirtos, Nick M, Tewari, Krishnansu S, Richards, William E, Nakayama, John M, Mutch, David G, Miller, David S, Matei, Daniela, and Wenzel, Lari B
- Abstract
IntroductionChemotherapy plus radiation (Cis-RT + CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of life (QOL), neurotoxicity (NTX) and psychometric properties of the gastrointestinal (GI) symptoms subscale during treatment and up to 1 year are described herein.MethodsQOL assessments were scheduled at baseline, 6 weeks (post completion of RT (Cis-RT + CP) or prior to cycle 3 (CP)), then 18 weeks (end of treatment) and 70 weeks (1 year after the end of treatment) after starting treatment. QOL instruments included the FACT-En TOI, FACT/GOG-neurotoxicity (Ntx) subscale (short), and the gastrointestinal (GI) symptoms subscale.ResultsAt the end of treatment, patients receiving Cis-RT + CP reported a statistically significant decreased QOL when compared to CP. The decline in QOL was reflected in physical well-being, functional well-being, and endometrial cancer specific concerns, but the minimally important differences (MID) were not considered clinically meaningful. Patients in both groups reported increased chemotherapy-induced Ntx symptoms with the CP group having worse scores and reaching peak symptoms at the time of chemotherapy completion. Patients on Cis-RT + CP reported statistically significantly worse GI symptoms after radiation therapy compared to patients on CP, this occurred across assessment intervals, though the MID was not meaningful. Psychometric evaluations indicated that the GI symptom scale is reliable, valid, and responsive to change.ConclusionsPROs indicate that the chemoradiotherapy group experienced worse HRQoL and GI toxicity compared to patients randomized to chemotherapy alone for locally advanced endometrial cancer though based on the MID, these were not clinically meaningful differences. The GI symptom subscale was a reliable and vali
- Published
- 2022
13. Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
- Author
-
Lee, Jung-Min, Lee, Jung-Min, Moore, Richard G, Ghamande, Sharad, Park, Min S, Diaz, John P, Chapman, Julia, Kendrick, James, Slomovitz, Brian M, Tewari, Krishnansu S, Lowe, Elizabeth S, Milenkova, Tsveta, Kumar, Sanjeev, Dymond, Mike, Brown, Jessica, Liu, Joyce F, Lee, Jung-Min, Lee, Jung-Min, Moore, Richard G, Ghamande, Sharad, Park, Min S, Diaz, John P, Chapman, Julia, Kendrick, James, Slomovitz, Brian M, Tewari, Krishnansu S, Lowe, Elizabeth S, Milenkova, Tsveta, Kumar, Sanjeev, Dymond, Mike, Brown, Jessica, and Liu, Joyce F
- Abstract
PurposeThe efficacy, safety, and tolerability of cediranib plus olaparib (cedi/ola) were investigated in patients with nongermline-BRCA-mutated (non-gBRCAm) platinum-resistant recurrent ovarian cancer.Patients and methodsPARP inhibitor-naïve women aged ≥18 years with platinum-resistant non-gBRCAm ovarian cancer, ECOG performance status of 0-2, and ≥3 prior lines of therapy received cediranib 30 mg once daily plus olaparib 200 mg twice daily in this single-arm, multicenter, phase IIb trial. The primary endpoint was objective response rate (ORR) by independent central review (ICR) using RECIST 1.1. Progression-free survival (PFS), overall survival (OS), and safety and tolerability were also examined.ResultsSixty patients received cedi/ola, all of whom had confirmed non-gBRCAm status. Patients had received a median of four lines of chemotherapy; most (88.3%) had received prior bevacizumab. ORR by ICR was 15.3%, median PFS was 5.1 months, and median OS was 13.2 months. Forty-four (73.3%) patients reported a grade ≥3 adverse event (AE), with one patient experiencing a grade 5 AE (sepsis), considered unrelated to the study treatment. Dose interruptions, reductions, and discontinuations due to AEs occurred in 55.0%, 18.3%, and 18.3% of patients, respectively. Patients with high global loss of heterozygosity (gLOH) had ORR of 26.7% [4/15; 95% confidence interval (CI), 7.8-55.1], while ORR was 12.5% (4/32; 95% CI, 3.5-29.0) in the low gLOH group.ConclusionsClinical activity was shown for the cedi/ola combination in heavily pretreated, non-gBRCAm, platinum-resistant patients with ovarian cancer despite failing to meet the target ORR of 20%, highlighting a need for further biomarker studies.
- Published
- 2022
14. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
- Author
-
Powell, Matthew A, Powell, Matthew A, Filiaci, Virginia L, Hensley, Martee L, Huang, Helen Q, Moore, Kathleen N, Tewari, Krishnansu S, Copeland, Larry J, Secord, Angeles A, Mutch, David G, Santin, Alessandro, Warshal, David P, Spirtos, Nick M, DiSilvestro, Paul A, Ioffe, Olga B, Miller, David S, Powell, Matthew A, Powell, Matthew A, Filiaci, Virginia L, Hensley, Martee L, Huang, Helen Q, Moore, Kathleen N, Tewari, Krishnansu S, Copeland, Larry J, Secord, Angeles A, Mutch, David G, Santin, Alessandro, Warshal, David P, Spirtos, Nick M, DiSilvestro, Paul A, Ioffe, Olga B, and Miller, David S
- Abstract
PurposeThis phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS).Patients and methodsAdults with chemotherapy-naïve UCS or ovarian carcinosarcoma (OCS) were randomly assigned to PC or PI with 3-week cycles for 6-10 cycles. With 264 events in patients with UCS, the power for an overall survival (OS) hybrid noninferiority design was 80% for a null hazard ratio (HR) of 1.2 against a 13% greater death rate on PI with a type I error of 5% for a one-tailed test.ResultsThe study enrolled 536 patients with UCS and 101 patients with OCS, with 449 and 90 eligible, respectively. Primary analysis was on patients with UCS, distributed as follows: 40% stage I, 6% stage II, 31% stage III, 15% stage IV, and 8% recurrent. Among eligible patients with UCS, PC was assigned to 228 and PI to 221. PC was not inferior to PI. The median OS was 37 versus 29 months (HR = 0.87; 90% CI, 0.70 to 1.075; P < .01 for noninferiority, P > .1 for superiority). The median progression-free survival was 16 versus 12 months (HR = 0.73; P = < 0.01 for noninferiority, P < .01 for superiority). Toxicities were similar, except that more patients in the PC arm had hematologic toxicity and more patients in the PI arm had confusion and genitourinary hemorrhage. Among 90 eligible patients with OCS, those in the PC arm had longer OS (30 v 25 months) and progression-free survival (15 v 10 months) than those in the PI arm, but with limited precision, these differences were not statistically significant.ConclusionPC was not inferior to the active regimen PI and should be standard treatment for UCS.
- Published
- 2022
15. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
- Author
-
duPont, Nefertiti C, duPont, Nefertiti C, Enserro, Danielle, Brady, Mark F, Moxley, Katherine, Walker, Joan L, Cosgrove, Casey, Bixel, Kristin, Tewari, Krishnansu S, Thaker, Premal, Wahner Hendrickson, Andrea E, Rubin, Stephen, Fujiwara, Keiichi, Casey, A Catherine, Soper, John, Burger, Robert A, Monk, Bradley J, duPont, Nefertiti C, duPont, Nefertiti C, Enserro, Danielle, Brady, Mark F, Moxley, Katherine, Walker, Joan L, Cosgrove, Casey, Bixel, Kristin, Tewari, Krishnansu S, Thaker, Premal, Wahner Hendrickson, Andrea E, Rubin, Stephen, Fujiwara, Keiichi, Casey, A Catherine, Soper, John, Burger, Robert A, and Monk, Bradley J
- Abstract
BackgroundAge and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy.MethodsWomen with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants.ResultsOne-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90).ConclusionsNon-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.
- Published
- 2022
16. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
- Author
-
Aghajanian, Carol, Aghajanian, Carol, Swisher, Elizabeth M, Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A, Fleming, Gini F, Friedlander, Michael, Moore, Kathleen N, Tewari, Krishnansu S, O'Malley, David M, Chan, John K, Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H, Coleman, Robert L, Aghajanian, Carol, Aghajanian, Carol, Swisher, Elizabeth M, Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A, Fleming, Gini F, Friedlander, Michael, Moore, Kathleen N, Tewari, Krishnansu S, O'Malley, David M, Chan, John K, Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H, and Coleman, Robert L
- Abstract
ObjectiveIn the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus chemotherapy alone. Here we present exploratory analyses by paclitaxel dosing schedule and germline BRCA (gBRCA) status.MethodsWomen with untreated ovarian carcinoma were randomized (1:1:1) to: veliparib during chemotherapy and maintenance (veliparib-throughout), veliparib during chemotherapy followed by placebo maintenance (veliparib-combination only), or placebo during chemotherapy and maintenance (control). Chemotherapy included carboplatin plus dose-dense (DD; weekly) or every-3-week (Q3W) paclitaxel (a stratification factor at randomization), selected at the investigator's discretion pre-randomization. PFS was assessed by paclitaxel dosing schedule using a Cox proportional hazard model adjusted by treatment arm and stratification factors; safety was analyzed based on paclitaxel dosing schedule and gBRCA status.Results1132 patients were analyzed by paclitaxel schedule. Pooled treatment arms demonstrated longer median PFS with DD (n = 586) versus Q3W (n = 546) paclitaxel (ITT: 20.5 vs 15.7 months, hazard ratio [HR] 0.77; homologous recombination proficient cancer: 15.1 vs 11.8 months, HR 0.64; BRCAwt: 18.0 vs 12.9 months, HR 0.70). Comparison between arms favored veliparib-throughout versus control in both DD (PFS, 24.2 vs 18.3 months, hazard ratio 0.67) and Q3W (19.3 vs 14.6, hazard ratio 0.69) subgroups. DD paclitaxel was associated with higher incidence of Grade 3/4 neutropenia, fatigue, and anemia versus Q3W. There were no differences in toxicity between gBRCAm (n = 211) and gBRCAwt (n = 902) subgroups.ConclusionsDD paclitaxel was tolerable and associated with longer PFS in the HR proficient and gBRCAwt groups, versus Q3W. gBRCA status did not impact safety
- Published
- 2022
17. Survival with Cemiplimab in Recurrent Cervical Cancer
- Author
-
Tewari, K, Monk, B, Vergote, I, Miller, A, de Melo, A, Kim, H, Kim, Y, Lisyanskaya, A, Samouëlian, V, Lorusso, D, Damian, F, Chang, C, Gotovkin, E, Takahashi, S, Ramone, D, Pikiel, J, Maćkowiak-Matejczyk, B, Guerra Alía, E, Colombo, N, Makarova, Y, Rischin, D, Lheureux, S, Hasegawa, K, Fujiwara, K, Li, J, Jamil, S, Jankovic, V, Chen, C, Seebach, F, Weinreich, D, Yancopoulos, G, Lowy, I, Mathias, M, Fury, M, Oaknin, A, Tewari, Krishnansu S, Monk, Bradley J, Vergote, Ignace, Miller, Austin, de Melo, Andreia C, Kim, Hee-Seung, Kim, Yong Man, Lisyanskaya, Alla, Samouëlian, Vanessa, Lorusso, Domenica, Damian, Fernanda, Chang, Chih-Long, Gotovkin, Evgeniy A, Takahashi, Shunji, Ramone, Daniella, Pikiel, Joanna, Maćkowiak-Matejczyk, Beata, Guerra Alía, Eva M, Colombo, Nicoletta, Makarova, Yulia, Rischin, Danny, Lheureux, Stephanie, Hasegawa, Kosei, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Jankovic, Vladimir, Chen, Chieh-I, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Mathias, Melissa, Fury, Matthew G, Oaknin, Ana, Tewari, K, Monk, B, Vergote, I, Miller, A, de Melo, A, Kim, H, Kim, Y, Lisyanskaya, A, Samouëlian, V, Lorusso, D, Damian, F, Chang, C, Gotovkin, E, Takahashi, S, Ramone, D, Pikiel, J, Maćkowiak-Matejczyk, B, Guerra Alía, E, Colombo, N, Makarova, Y, Rischin, D, Lheureux, S, Hasegawa, K, Fujiwara, K, Li, J, Jamil, S, Jankovic, V, Chen, C, Seebach, F, Weinreich, D, Yancopoulos, G, Lowy, I, Mathias, M, Fury, M, Oaknin, A, Tewari, Krishnansu S, Monk, Bradley J, Vergote, Ignace, Miller, Austin, de Melo, Andreia C, Kim, Hee-Seung, Kim, Yong Man, Lisyanskaya, Alla, Samouëlian, Vanessa, Lorusso, Domenica, Damian, Fernanda, Chang, Chih-Long, Gotovkin, Evgeniy A, Takahashi, Shunji, Ramone, Daniella, Pikiel, Joanna, Maćkowiak-Matejczyk, Beata, Guerra Alía, Eva M, Colombo, Nicoletta, Makarova, Yulia, Rischin, Danny, Lheureux, Stephanie, Hasegawa, Kosei, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Jankovic, Vladimir, Chen, Chieh-I, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Mathias, Melissa, Fury, Matthew G, and Oaknin, Ana
- Abstract
Background: Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)-blocking antibody approved to treat lung and skin cancers, has been shown to have preliminary clinical activity in this population. Methods: In this phase 3 trial, we enrolled patients who had disease progression after first-line platinum-containing chemotherapy, regardless of their programmed cell death ligand 1 (PD-L1) status. Women were randomly assigned (1:1) to receive cemiplimab (350 mg every 3 weeks) or the investigator's choice of single-agent chemotherapy. The primary end point was overall survival. Progression-free survival and safety were also assessed. Results: A total of 608 women were enrolled (304 in each group). In the overall trial population, median overall survival was longer in the cemiplimab group than in the chemotherapy group (12.0 months vs. 8.5 months; hazard ratio for death, 0.69; 95% confidence interval [CI], 0.56 to 0.84; two-sided P<0.001). The overall survival benefit was consistent in both histologic subgroups (squamous-cell carcinoma and adenocarcinoma [including adenosquamous carcinoma]). Progression-free survival was also longer in the cemiplimab group than in the chemotherapy group in the overall population (hazard ratio for disease progression or death, 0.75; 95% CI, 0.63 to 0.89; two-sided P<0.001). In the overall population, an objective response occurred in 16.4% (95% CI, 12.5 to 21.1) of the patients in the cemiplimab group, as compared with 6.3% (95% CI, 3.8 to 9.6) in the chemotherapy group. An objective response occurred in 18% (95% CI, 11 to 28) of the cemiplimab-treated patients with PD-L1 expression greater than or equal to 1% and in 11% (95% CI, 4 to 25) of those with PD-L1 expression of less than 1%. Overall, grade 3 or higher adverse events occurred in 45.0% of the patients who received cemiplimab and in 53.4% of those who received chemotherapy. Conclusions: Survival was significa
- Published
- 2022
18. Therapeutic vaccination using HPV 16 E7 to eradicate CIN3.
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Tewari, Krishnansu S, and Tewari, Krishnansu S
- Published
- 2019
19. Therapeutic vaccination using HPV 16 E7 to eradicate CIN3.
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Tewari, Krishnansu S, and Tewari, Krishnansu S
- Published
- 2019
20. Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Monk, Bradley J, Tewari, Krishnansu S, Tewari, Krishnansu S, and Monk, Bradley J
- Published
- 2019
21. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Burger, Robert A, Enserro, Danielle, Norquist, Barbara M, Swisher, Elizabeth M, Brady, Mark F, Bookman, Michael A, Fleming, Gini F, Huang, Helen, Homesley, Howard D, Fowler, Jeffrey M, Greer, Benjamin E, Boente, Matthew, Liang, Sharon X, Ye, Chenglin, Bais, Carlos, Randall, Leslie M, Chan, John K, Ferriss, J Stuart, Coleman, Robert L, Aghajanian, Carol, Herzog, Thomas J, DiSaia, Philip J, Copeland, Larry J, Mannel, Robert S, Birrer, Michael J, Monk, Bradley J, Tewari, Krishnansu S, Tewari, Krishnansu S, Burger, Robert A, Enserro, Danielle, Norquist, Barbara M, Swisher, Elizabeth M, Brady, Mark F, Bookman, Michael A, Fleming, Gini F, Huang, Helen, Homesley, Howard D, Fowler, Jeffrey M, Greer, Benjamin E, Boente, Matthew, Liang, Sharon X, Ye, Chenglin, Bais, Carlos, Randall, Leslie M, Chan, John K, Ferriss, J Stuart, Coleman, Robert L, Aghajanian, Carol, Herzog, Thomas J, DiSaia, Philip J, Copeland, Larry J, Mannel, Robert S, Birrer, Michael J, and Monk, Bradley J
- Abstract
PurposeWe report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma.MethodsA total of 1,873 women with incompletely resected stage III to IV disease were randomly assigned 1:1:1 to six 21-day cycles of intravenous carboplatin (area under the concentration v time curve 6) and paclitaxel (175 mg/m2) versus chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6) versus chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22). Inclusion criteria included a Gynecologic Oncology Group performance status of 0 to 2 and no history of clinically significant vascular events or evidence of intestinal obstruction. OS was analyzed in the intention-to-treat population. A total of 1,195 serum and/or tumor specimens were sequenced for BRCA1/2 and damaging mutations in homologous recombination repair (HRR) genes. Intratumoral microvessel density was studied using CD31 immunohistochemistry.ResultsMedian follow-up was 102.9 months. Relative to control (n = 625), for patients receiving bevacizumab-concurrent (n = 625), the hazard ratio (HR) of death was 1.06 (95% CI, 0.94 to 1.20); for bevacizumab-concurrent plus maintenance (n = 623), the HR was 0.96 (95% CI, 0.85 to 1.09). Disease-specific survival was not improved in any arm. No survival advantage was observed after censoring patients who received bevacizumab at crossover or as second line. Median OS for stage IV bevacizumab-concurrent plus maintenance was 42.8 v 32.6 months for stage IV control (HR, 0.75; 95% CI, 0.59 to 0.95). Relative to wild type, the HR for death for BRCA1/2 mutated carcinomas was 0.62 (95% CI, 0.52 to 0.73), and for non-BRCA1/2 HRR, the HR was 0.65 (95% CI, 0.51 to 0.85). BRCA1/2, HRR, and CD31 were not predictive of bevacizumab activity.ConclusionNo survival differences were observed for patients who received bevacizumab compar
- Published
- 2019
22. Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?
- Author
-
Bujnak, Alyssa C, Bujnak, Alyssa C, Tewari, Krishnansu S, Bujnak, Alyssa C, Bujnak, Alyssa C, and Tewari, Krishnansu S
- Published
- 2021
23. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II
- Author
-
Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjolhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., O'Malley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Pär, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G. J., Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjolhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., O'Malley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Pär, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G. J.
- Abstract
PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients wit
- Published
- 2021
- Full Text
- View/download PDF
24. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II
- Author
-
Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G. J., Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G. J.
- Abstract
PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity., Funding Agencies|Dutch Cancer Society (KWF Kankerbestrijding)KWF Kankerbestrijding; NRG Oncology
- Published
- 2021
- Full Text
- View/download PDF
25. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II
- Author
-
Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G. J., Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G. J.
- Abstract
PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity., Funding Agencies|Dutch Cancer Society (KWF Kankerbestrijding)KWF Kankerbestrijding; NRG Oncology
- Published
- 2021
- Full Text
- View/download PDF
26. Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?
- Author
-
Bujnak, Alyssa C, Bujnak, Alyssa C, Tewari, Krishnansu S, Bujnak, Alyssa C, Bujnak, Alyssa C, and Tewari, Krishnansu S
- Published
- 2021
27. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
- Author
-
Leslie, Kimberly K, Leslie, Kimberly K, Filiaci, Virginia L, Mallen, Adrianne R, Thiel, Kristina W, Devor, Eric J, Moxley, Katherine, Richardson, Debra, Mutch, David, Secord, Angeles Alvarez, Tewari, Krishnansu S, McDonald, Megan E, Mathews, Cara, Cosgrove, Casey, Dewdney, Summer, Casablanca, Yovanni, Jackson, Amanda, Rose, Peter G, Zhou, XunClare, McHale, Michael, Lankes, Heather, Levine, Douglas A, Aghajanian, Carol, Leslie, Kimberly K, Leslie, Kimberly K, Filiaci, Virginia L, Mallen, Adrianne R, Thiel, Kristina W, Devor, Eric J, Moxley, Katherine, Richardson, Debra, Mutch, David, Secord, Angeles Alvarez, Tewari, Krishnansu S, McDonald, Megan E, Mathews, Cara, Cosgrove, Casey, Dewdney, Summer, Casablanca, Yovanni, Jackson, Amanda, Rose, Peter G, Zhou, XunClare, McHale, Michael, Lankes, Heather, Levine, Douglas A, and Aghajanian, Carol
- Abstract
BackgroundSuccessfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivity. NRG Oncology/Gynecologic Oncology Group (GOG) Study GOG-86P was one of the first attempts to combine targeted agents (bevacizumab or temsirolimus) with chemotherapy in patients with advanced endometrial cancer. Herein we performed exploratory analyses to examine the relationship between mutations in TP53, the most commonly mutated gene in cancer, with outcomes on GOG-86P.MethodsTP53 mutational status was determined and correlated with progression-free survival (PFS) and overall survival (OS) on GOG-86P.ResultsMutations in TP53 were associated with improved PFS and OS for patients that received bevacizumab as compared to temsirolimus (PFS: HR 0.48, 95% CI 0.31, 0.75; OS: HR: 0.61, 95% CI 0.38, 0.98). By contrast, there was no statistically significant difference in PFS or OS between arms for cases with WT TP53.ConclusionsThis exploratory study suggests that combining chemotherapy with bevacizumab, but not temsirolimus, may enhance PFS and OS for patients whose tumors harbor mutant p53. These data set the stage for larger clinical studies evaluating the potential of TP53 mutational status as a biomarker to guide choice of treatment for endometrial cancer patients. Clintrials.gov: NCT00977574.
- Published
- 2021
28. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.
- Author
-
Oonk, Maaike HM, Oonk, Maaike HM, Slomovitz, Brian, Baldwin, Peter JW, van Doorn, Helena C, van der Velden, Jacobus, de Hullu, Joanne A, Gaarenstroom, Katja N, Slangen, Brigitte FM, Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora BL, van Driel, Willemien J, Hermans, Ralph H, Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M, Sharma, Aarti, DiSilvestro, Paul A, Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B, Luesley, David, Ellis, Patricia, Duncan, Timothy J, Tjiong, Ming Y, Cruickshank, Derek J, Kjølhede, Preben, Levenback, Charles F, Bouda, Jiri, Kieser, Katharina E, Palle, Connie, Spirtos, Nicola M, O'Malley, David M, Leitao, Mario M, Geller, Melissa A, Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H, Borgfeldt, Christer, Lea, Jayanthi S, Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S, Manchanda, Ranjit, Jensen, Pernille T, Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H, Monk, Bradley J, Creutzberg, Carien L, van der Zee, Ate GJ, Oonk, Maaike HM, Oonk, Maaike HM, Slomovitz, Brian, Baldwin, Peter JW, van Doorn, Helena C, van der Velden, Jacobus, de Hullu, Joanne A, Gaarenstroom, Katja N, Slangen, Brigitte FM, Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora BL, van Driel, Willemien J, Hermans, Ralph H, Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M, Sharma, Aarti, DiSilvestro, Paul A, Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B, Luesley, David, Ellis, Patricia, Duncan, Timothy J, Tjiong, Ming Y, Cruickshank, Derek J, Kjølhede, Preben, Levenback, Charles F, Bouda, Jiri, Kieser, Katharina E, Palle, Connie, Spirtos, Nicola M, O'Malley, David M, Leitao, Mario M, Geller, Melissa A, Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H, Borgfeldt, Christer, Lea, Jayanthi S, Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S, Manchanda, Ranjit, Jensen, Pernille T, Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H, Monk, Bradley J, Creutzberg, Carien L, and van der Zee, Ate GJ
- Abstract
PurposeThe Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN).MethodsGROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences.ResultsFrom December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL.ConclusionInguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrom
- Published
- 2021
29. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.
- Author
-
Levinson, Kimberly, Levinson, Kimberly, Beavis, Anna L, Purdy, Christopher, Rositch, Anne F, Viswanathan, Akila, Wolfson, Aaron H, Kelly, Michael G, Tewari, Krishnansu S, McNally, Leah, Guntupalli, Saketh R, Ragab, Omar, Lee, Yi-Chun, Miller, David S, Huh, Warner K, Wilkinson, Kelly J, Spirtos, Nicola M, Van Le, Linda, Casablanca, Yovanni, Holman, Laura L, Waggoner, Steven E, Fader, Amanda N, Levinson, Kimberly, Levinson, Kimberly, Beavis, Anna L, Purdy, Christopher, Rositch, Anne F, Viswanathan, Akila, Wolfson, Aaron H, Kelly, Michael G, Tewari, Krishnansu S, McNally, Leah, Guntupalli, Saketh R, Ragab, Omar, Lee, Yi-Chun, Miller, David S, Huh, Warner K, Wilkinson, Kelly J, Spirtos, Nicola M, Van Le, Linda, Casablanca, Yovanni, Holman, Laura L, Waggoner, Steven E, and Fader, Amanda N
- Abstract
PurposeThe Sedlis criteria define risk factors for recurrence warranting post-hysterectomy radiation for early-stage cervical cancer; however, these factors were defined for squamous cell carcinoma (SCC) at an estimated recurrence risk of ≥30%. Our study evaluates and compares risk factors for recurrence for cervical SCC compared with adenocarcinoma (AC) and develops histology-specific nomograms to estimate risk of recurrence and guide adjuvant treatment.MethodsWe performed an ancillary analysis of GOG 49, 92, and 141, and included stage I patients who were surgically managed and received no neoadjuvant/adjuvant therapy. Multivariable Cox proportional hazards models were used to evaluate independent risk factors for recurrence by histology and to generate prognostic histology-specific nomograms for 3-year recurrence risk.ResultsWe identified 715 patients with SCC and 105 with AC; 20% with SCC and 17% with AC recurred. For SCC, lymphvascular space invasion (LVSI: HR 1.58, CI 1.12-2.22), tumor size (TS ≥4 cm: HR 2.67, CI 1.67-4.29), and depth of invasion (DOI; middle 1/3, HR 4.31, CI 1.81-10.26; deep 1/3, HR 7.05, CI 2.99-16.64) were associated with recurrence. For AC, only TS ≥4 cm, was associated with recurrence (HR 4.69, CI 1.25-17.63). For both histologies, there was an interaction effect between TS and LVSI. For those with SCC, DOI was most associated with recurrence (16% risk); for AC, TS conferred a 15% risk with negative LVSI versus a 25% risk with positive LVSI.ConclusionsCurrent treatment standards are based on the Sedlis criteria, specifically derived from data on SCC. However, risk factors for recurrence differ for squamous cell and adenocarcinoma of the cervix. Histology-specific nomograms accurately and linearly represent risk of recurrence for both SCC and AC tumors and may provide a more contemporary and tailored tool for clinicians to base adjuvant treatment recommendations to their patients with cervical cancer.
- Published
- 2021
30. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
- Author
-
Buechel, Megan E, Buechel, Megan E, Enserro, Danielle, Burger, Robert A, Brady, Mark F, Wade, Katrina, Secord, Angeles Alvarez, Nixon, Andrew B, Mirniaharikandehei, Seyedehnafiseh, Liu, Hong, Zheng, Bin, O'Malley, David M, Gray, Heidi, Tewari, Krishnansu S, Mannel, Robert S, Birrer, Michael J, Moore, Kathleen N, Buechel, Megan E, Buechel, Megan E, Enserro, Danielle, Burger, Robert A, Brady, Mark F, Wade, Katrina, Secord, Angeles Alvarez, Nixon, Andrew B, Mirniaharikandehei, Seyedehnafiseh, Liu, Hong, Zheng, Bin, O'Malley, David M, Gray, Heidi, Tewari, Krishnansu S, Mannel, Robert S, Birrer, Michael J, and Moore, Kathleen N
- Abstract
PurposeIncreasing measures of adiposity have been correlated with poor oncologic outcomes and a lack of response to anti-angiogenic therapies. Limited data exists on the impact of subcutaneous fat density (SFD) and visceral fat density (VFD) on oncologic outcomes. This ancillary analysis of GOG-218, evaluates whether imaging markers of adiposity were predictive biomarkers for bevacizumab (bev) use in epithelial ovarian cancer (EOC).Patients and methodsThere were 1249 patients (67%) from GOG-218 with imaging measurements. SFD and VFD were calculated utilizing Hounsfield units (HU). Proportional hazards models were used to assess the association between SFD and VFD with overall survival (OS).ResultsIncreased SFD and VFD showed an increased HR for death (HR per 1-SD increase 1.12, 95% CI:1.05-1.19 p = 0.0009 and 1.13, 95% CI: 1.05-1.20 p = 0.0006 respectively). In the predictive analysis for response to bev, high VFD showed an increased hazard for death in the placebo group (HR per 1-SD increase 1.22, 95% CI: 1.09-1.37; p = 0.025). However, in the bev group there was no effect seen (HR per 1-SD increase: 1.01, 95% CI: 0.90-1.14) Median OS was 45 vs 47 months in the VFD low groups and 36 vs 42 months in the VFD high groups on placebo versus bev, respectively.ConclusionHigh VFD and SFD have a negative prognostic impact on patients with EOC. High VFD appears to be a predictive marker of bev response and patients with high VFD may be more likely to benefit from initial treatment with bev.
- Published
- 2021
31. De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening.
- Author
-
Hahn, Erin E, Hahn, Erin E, Munoz-Plaza, Corrine, Altman, Danielle E, Hsu, Chunyi, Cannizzaro, Nancy T, Ngo-Metzger, Quyen, Wride, Patricia, Gould, Michael K, Mittman, Brian S, Hodeib, Melissa, Tewari, Krishnansu S, Ajamian, Lena H, Eskander, Ramez N, Tewari, Devansu, Chao, Chun R, Hahn, Erin E, Hahn, Erin E, Munoz-Plaza, Corrine, Altman, Danielle E, Hsu, Chunyi, Cannizzaro, Nancy T, Ngo-Metzger, Quyen, Wride, Patricia, Gould, Michael K, Mittman, Brian S, Hodeib, Melissa, Tewari, Krishnansu S, Ajamian, Lena H, Eskander, Ramez N, Tewari, Devansu, and Chao, Chun R
- Abstract
BackgroundNew cervical cancer screening guidelines recommend primary human papillomavirus (HPV) testing for women age 30-65 years. Healthcare organizations are preparing to de-implement the previous recommended strategies of Pap testing or co-testing (Pap plus HPV test) and substitute primary HPV testing. However, there may be significant challenges to the replacement of this entrenched clinical practice, even with an evidence-based substitution. We sought to identify stakeholder-perceived barriers and facilitators to this substitution within a large healthcare system, Kaiser Permanente Southern California.MethodsWe conducted semi-structured qualitative interviews with clinician, administrative, and patient stakeholders regarding (a) acceptability and feasibility of the planned substitution; (b) perceptions of barriers and facilitators, with an emphasis on those related to the de-implementation/implementation cycle of substitution; and (c) perceived readiness to change. Our interview guide was informed by the Consolidated Framework for Implementation Research (CFIR). Using a team coding approach, we developed an initial coding structure refined during iterative analysis; the data were subsequently organized thematically into domains, key themes, and sub-themes using thematic analysis, followed by framework analysis informed by CFIR.ResultsWe conducted 23 interviews: 5 patient and 18 clinical/administrative. Clinicians perceived that patients feel more tests equals better care, and clinicians and patients expressed fear of missed cancers ("…it'll be more challenging convincing the patient that only one test is…good enough to detect cancer."). Patients perceived practice changes resulting in "less care" are driven by the desire to cut costs. In contrast, clinicians/administrators viewed changing from two tests to one as acceptable and a workflow efficiency ("…It's very easy and half the work."). Stakeholder-recommended strategies included focusing on the increased eff
- Published
- 2021
32. Corrigendum to 'Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis' [Gynecologic Oncology 162 (2021) 532-538].
- Author
-
Levinson, Kimberly, Levinson, Kimberly, Beavis, Anna L, Purdy, Christopher, Rositch, Anne F, Viswanathan, Akila, Wolfson, Aaron H, Kelly, Michael G, Tewari, Krishnansu S, McNally, Leah, Guntupalli, Saketh R, Ragab, Omar, Lee, Yi-Chun, Miller, David S, Huh, Warner K, Wilkinson, Kelly J, Spirtos, Nicola M, Le, Linda Van, Casablanca, Yovanni, Holman, Laura L, Waggoner, Steven E, Fader, Amanda N, Levinson, Kimberly, Levinson, Kimberly, Beavis, Anna L, Purdy, Christopher, Rositch, Anne F, Viswanathan, Akila, Wolfson, Aaron H, Kelly, Michael G, Tewari, Krishnansu S, McNally, Leah, Guntupalli, Saketh R, Ragab, Omar, Lee, Yi-Chun, Miller, David S, Huh, Warner K, Wilkinson, Kelly J, Spirtos, Nicola M, Le, Linda Van, Casablanca, Yovanni, Holman, Laura L, Waggoner, Steven E, and Fader, Amanda N
- Abstract
The authors regret that the version of Table 3 originally published in this article was incorrect. The online version has now been updated and the correct table can be found below. The authors would like to apologise for any inconvenience caused. Table 3. Comparison of 3 yr RFS, nomogram recurrence risk, and Sedlis criteria for predictor variable combinations. [Table Presented]
- Published
- 2021
33. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II
- Author
-
Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G. J., Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G. J.
- Abstract
PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity., Funding Agencies|Dutch Cancer Society (KWF Kankerbestrijding)KWF Kankerbestrijding; NRG Oncology
- Published
- 2021
- Full Text
- View/download PDF
34. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
- Author
-
Colombo, N, Dubot, C, Lorusso, D, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Tewari, K, Salman, P, Hoyos Usta, E, Yañez, E, Gümüş, M, Olivera Hurtado de Mendoza, M, Samouëlian, V, Castonguay, V, Arkhipov, A, Toker, S, Li, K, Keefe, S, Monk, B, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu S, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen M, Monk, Bradley J, Colombo, N, Dubot, C, Lorusso, D, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Tewari, K, Salman, P, Hoyos Usta, E, Yañez, E, Gümüş, M, Olivera Hurtado de Mendoza, M, Samouëlian, V, Castonguay, V, Arkhipov, A, Toker, S, Li, K, Keefe, S, Monk, B, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu S, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen M, and Monk, Bradley J
- Abstract
BACKGROUND Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with or without bevacizumab. METHODS In a double-blind, phase 3 trial, we randomly assigned patients with persistent, recurrent, or metastatic cervical cancer in a 1:1 ratio to receive pembrolizumab (200 mg) or placebo every 3 weeks for up to 35 cycles plus platinum-based chemotherapy and, per investigator discretion, bevacizumab. The dual primary end points were progression-free survival and overall survival, each tested sequentially in patients with a PD-L1 combined positive score of 1 or more, in the intention-to-treat population, and in patients with a PD-L1 combined positive score of 10 or more. The combined positive score is defined as the number of PD-L1–staining cells divided by the total number of viable tumor cells, multiplied by 100. All results are from the protocol-specified first interim analysis. RESULTS In 548 patients with a PD-L1 combined positive score of 1 or more, median progression-free survival was 10.4 months in the pembrolizumab group and 8.2 months in the placebo group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.50 to 0.77; P<0.001). In 617 patients in the intention-to-treat population, progression-free survival was 10.4 months and 8.2 months, respectively (hazard ratio, 0.65; 95% CI, 0.53 to 0.79; P<0.001). In 317 patients with a PD-L1 combined positive score of 10 or more, progression-free survival was 10.4 months and 8.1 months, respectively (hazard ratio, 0.58; 95% CI, 0.44 to 0.77; P<0.001). Overall survival at 24 months was 53.0% in the pembrolizumab group and 41.7% in the placebo group (hazard ratio for death, 0.64; 95% CI, 0.50 to 0.81; P<0.001), 50.4% and 40.4% (hazard ratio, 0.67; 95% CI, 0.54 to 0.84; P<0.001), and 54.4% and 44.6% (hazar
- Published
- 2021
35. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II
- Author
-
Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G. J., Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G. J.
- Abstract
PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity., Funding Agencies|Dutch Cancer Society (KWF Kankerbestrijding)KWF Kankerbestrijding; NRG Oncology
- Published
- 2021
- Full Text
- View/download PDF
36. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II
- Author
-
Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G. J., Oonk, Maaike H. M., Slomovitz, Brian, Baldwin, Peter J. W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F. M., Vergote, Ignace, Brannstrom, Mats, van Dorst, Eleonora B. L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjölhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., OMalley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G. J.
- Abstract
PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (<= 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity., Funding Agencies|Dutch Cancer Society (KWF Kankerbestrijding)KWF Kankerbestrijding; NRG Oncology
- Published
- 2021
- Full Text
- View/download PDF
37. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node:Results of GROINSS-V II
- Author
-
Oonk, Maaike H.M., Slomovitz, Brian, Baldwin, Peter J.W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F.M., Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora B.L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjølhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., O'Malley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., van der Zee, Ate G.J., Oonk, Maaike H.M., Slomovitz, Brian, Baldwin, Peter J.W., van Doorn, Helena C., van der Velden, Jacobus, de Hullu, Joanne A., Gaarenstroom, Katja N., Slangen, Brigitte F.M., Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora B.L., van Driel, Willemien J., Hermans, Ralph H., Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M., Sharma, Aarti, DiSilvestro, Paul A., Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B., Luesley, David, Ellis, Patricia, Duncan, Timothy J., Tjiong, Ming Y., Cruickshank, Derek J., Kjølhede, Preben, Levenback, Charles F., Bouda, Jiri, Kieser, Katharina E., Palle, Connie, Spirtos, Nicola M., O'Malley, David M., Leitao, Mario M., Geller, Melissa A., Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H., Borgfeldt, Christer, Lea, Jayanthi S., Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S., Manchanda, Ranjit, Jensen, Pernille T., Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H., Monk, Bradley J., Creutzberg, Carien L., and van der Zee, Ate G.J.
- Abstract
PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients
- Published
- 2021
38. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
- Author
-
Haunschild, Carolyn E, Haunschild, Carolyn E, Tewari, Krishnansu S, Haunschild, Carolyn E, Haunschild, Carolyn E, and Tewari, Krishnansu S
- Abstract
On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National Cancer Institute-sponsored Gynecologic Oncology Group (GOG) protocol 0218, the Phase III, randomized, placebo-controlled, double-blind, multi-center and multi-national clinical trial that met its primary end point, progression-free survival. Bevacizumab is now approved in the frontline, platinum-sensitive recurrent and platinum-resistant recurrent settings for epithelial ovarian cancer. This review will address the broad range of clinical trials addressing the efficacy of bevacizumab use in ovarian cancer.
- Published
- 2020
39. Robotic surgery for gynecologic cancers: indications, techniques and controversies.
- Author
-
Clair, Kiran H, Clair, Kiran H, Tewari, Krishnansu S, Clair, Kiran H, Clair, Kiran H, and Tewari, Krishnansu S
- Abstract
Minimally invasive surgery for gynecologic cancers is associated with fewer postoperative complications including less blood loss and quicker recovery time compared to traditional laparotomy. The robotic platform has allowed patients access to minimally invasive surgery due to its increased utilization by gynecologic oncologists. Many surgeons have embraced the robotic platform due to its technological advances over traditional laparoscopy including high-definition 3D optics, wristed instrumentation, camera stability and improved ergonomics. While robotic surgery continues as a mainstay in the management of gynecologic cancers, it remains controversial in regards to its cost effectiveness and more recently, its long-term impact on clinical and oncologic outcomes. A strong component of the justification of this surgical platform is based on extrapolated data from traditional laparoscopy despite limited prospective randomized trials for robotic-assisted surgery. In this review, we highlight the use of robotic surgery in the management of gynecologic cancers in special populations: fertility sparing patients, the morbidly obese, the elderly, and patients with a favorable response to neoadjuvant chemotherapy.
- Published
- 2020
40. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
- Author
-
Miller, David S, Miller, David S, Filiaci, Virginia L, Mannel, Robert S, Cohn, David E, Matsumoto, Takashi, Tewari, Krishnansu S, DiSilvestro, Paul, Pearl, Michael L, Argenta, Peter A, Powell, Matthew A, Zweizig, Susan L, Warshal, David P, Hanjani, Parviz, Carney, Michael E, Huang, Helen, Cella, David, Zaino, Richard, Fleming, Gini F, Miller, David S, Miller, David S, Filiaci, Virginia L, Mannel, Robert S, Cohn, David E, Matsumoto, Takashi, Tewari, Krishnansu S, DiSilvestro, Paul, Pearl, Michael L, Argenta, Peter A, Powell, Matthew A, Zweizig, Susan L, Warshal, David P, Hanjani, Parviz, Carney, Michael E, Huang, Helen, Cella, David, Zaino, Richard, and Fleming, Gini F
- Abstract
PurposeLimitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP.MethodsGOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance status 0-2; and adequate renal, hepatic, and marrow function. Prior radiotherapy and/or hormonal therapy were permitted, but chemotherapy, including radiosensitization, was not. Patients were treated with doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with granulocyte colony-stimulating factor or paclitaxel 175 mg/m2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles. The primary endpoint was overall survival (OS; modified intention to treat). Progression-free survival (PFS), health-related quality of life (HRQoL), and toxicity were secondary endpoints.ResultsFrom 2003 to 2009, 1,381 women were enrolled. Noninferiority of TC to TAP was concluded for OS (median, 37 v 41 months, respectively; hazard ratio [HR], 1.002; 90% CI, 0.9 to 1.12), and PFS (median, 13 v 14 months; HR, 1.032; 90% CI, 0.93 to 1.15). Neutropenic fever was reported in 7% of patients receiving TAP and 6% of those receiving TC. Grade > 2 sensory neuropathy was recorded in 26% of patients receiving TAP and 20% receiving TC (P = .40). More grade ≥ 3 thrombocytopenia (23% v 12%), vomiting (7% v 4%), diarrhea (6% v 2%), and metabolic (14% v 8%) toxicities were reported with TAP. Neutropenia (52% v 80%) was more common with TC. Small HRQoL differences favored TC.ConclusionWith demonstrated noninferiority to TAP, TC is the global first-line standard for advanced endometrial cancer.
- Published
- 2020
41. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
- Author
-
Wolford, Juliet E, Wolford, Juliet E, Bai, Jiaru, Moore, Kathleen N, Kristeleit, Rebecca, Monk, Bradley J, Tewari, Krishnansu S, Wolford, Juliet E, Wolford, Juliet E, Bai, Jiaru, Moore, Kathleen N, Kristeleit, Rebecca, Monk, Bradley J, and Tewari, Krishnansu S
- Abstract
BACKGROUND:Olaparib was approved on December 19, 2014 by the US FDA as 4th-line therapy (and beyond) for patients with germline BRCA1/2 mutations; rucaparib was approved on December 19, 2016 as 3rd-line therapy (and beyond) for germline or somatic BRCA1/2-mutated recurrent disease. On October 23, 2019, niraparib was approved for treatment of women with damaging mutations in BRCA1/2 or other homologous recombination repair genes who had been treated with three or more prior regimens. We compared the cost-effectiveness of PARPi(s) with intravenous regimens for platinum-resistant disease. METHODS:Median progression-free survival (PFS) and toxicity data from regulatory trials were incorporated in a model which transitioned patients through response, hematologic complications, non-hematologic complications, progression, and death. Using TreeAge Pro 2017, each PARPi(s) was compared separately to non‑platinum-based and bevacizumab-containing regimens. Costs of IV drugs, managing toxicities, infusions, and supportive care were estimated using 2017 Medicare data. Incremental cost-effectiveness ratios (ICERs) were calculated and PFS was reported in quality adjusted life months for platinum-resistant populations. RESULTS:Non‑platinum-based intravenous chemotherapy was most cost effective ($6,412/PFS-month) compared with bevacizumab-containing regimens ($12,187/PFS-month), niraparib ($18,970/PFS-month), olaparib ($16,327/PFS-month), and rucaparib ($16,637/PFS-month). ICERs for PARPi(s) were 3-3.5× times greater than intravenous non‑platinum-based regimens. CONCLUSION:High costs of orally administered PARPi(s) were not mitigated or balanced by costs of infusion and managing toxicities of intravenous regimens typically associated with lower response and shorter median PFS. Balancing modest clinical benefit with costs of novel therapies remains problematic and could widen disparities among those with limited access to care.
- Published
- 2020
42. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
- Author
-
Alvarez Secord, Angeles, Alvarez Secord, Angeles, Bell Burdett, Kirsten, Owzar, Kouros, Tritchler, David, Sibley, Alexander B, Liu, Yingmiao, Starr, Mark D, Brady, J Chris, Lankes, Heather A, Hurwitz, Herbert I, Mannel, Robert S, Tewari, Krishnansu S, O'Malley, David M, Gray, Heidi, Bakkum-Gamez, Jamie N, Fujiwara, Keiichi, Boente, Matthew, Deng, Wei, Burger, Robert A, Birrer, Michael J, Nixon, Andrew B, Alvarez Secord, Angeles, Alvarez Secord, Angeles, Bell Burdett, Kirsten, Owzar, Kouros, Tritchler, David, Sibley, Alexander B, Liu, Yingmiao, Starr, Mark D, Brady, J Chris, Lankes, Heather A, Hurwitz, Herbert I, Mannel, Robert S, Tewari, Krishnansu S, O'Malley, David M, Gray, Heidi, Bakkum-Gamez, Jamie N, Fujiwara, Keiichi, Boente, Matthew, Deng, Wei, Burger, Robert A, Birrer, Michael J, and Nixon, Andrew B
- Abstract
PurposeGOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free survival (PFS), but no overall survival (OS) benefit with bevacizumab. Blood samples were collected for biomarker analyses.Experimental designPlasma samples were analyzed via multiplex ELISA technology for seven prespecified biomarkers [IL6, Ang-2, osteopontin (OPN), stromal cell-derived factor-1 (SDF-1), VEGF-D, IL6 receptor (IL6R), and GP130]. The predictive value of each biomarker with respect to PFS and OS was assessed using a protein marker by treatment interaction term within the framework of a Cox proportional hazards model. Prognostic markers were identified using Cox models adjusted for baseline covariates.ResultsBaseline samples were available from 751 patients. According to our prespecified analysis plan, IL6 was predictive of a therapeutic advantage with bevacizumab for PFS (P = 0.007) and OS (P = 0.003). IL6 and OPN were found to be negative prognostic markers for both PFS and OS (P < 0.001). Patients with high median IL6 levels (dichotomized at the median) treated with bevacizumab had longer PFS (14.2 vs. 8.7 months) and OS (39.6 vs. 33.1 months) compared with placebo.ConclusionsThe inflammatory cytokine IL6 may be predictive of therapeutic benefit from bevacizumab when combined with carboplatin and paclitaxel. Aligning with results observed in patients with renal cancer treated with antiangiogenic therapies, it appears plasma IL6 may also define those patients with EOC more or less likely to benefit from the addition of bevacizumab to standard chemotherapy.
- Published
- 2020
43. Gynecologic cancer in pregnancy.
- Author
-
Korenaga, Travis-Riley K, Korenaga, Travis-Riley K, Tewari, Krishnansu S, Korenaga, Travis-Riley K, Korenaga, Travis-Riley K, and Tewari, Krishnansu S
- Abstract
Cancer complicates 1 in 1000 pregnancies. Multidisciplinary consensus comprised of Gynecologic Oncology, Pathology, Neonatology, Radiology, Anesthesiology, Maternal Fetal Medicine, and Social Work should be convened. Pregnancy provides an opportunity for cervical cancer screening, with deliberate delays in treatment permissible for early stage carcinoma. Vaginal delivery is contraindicated in the presence of gross lesion(s) and radical hysterectomy with lymphadenectomy at cesarean delivery is recommended. Women with locally advanced and metastatic/recurrent disease should commence treatment at diagnosis with chemoradiation and systemic therapy, respectively; neoadjuvant chemotherapy to permit gestational advancement may be considered in select cases. Most adnexal masses are benign and resolve by the second trimester. Persistent, asymptomatic, benign-appearing masses can be managed conservatively; surgery, if indicated, is best deferred to 15-20 weeks, with laparoscopy preferable over laparotomy whenever possible. Benign and malignant germ cell tumors and borderline tumors are occasionally encountered, with unilateral adnexectomy and preservation of the uterus and contralateral ovary being the rule. Epithelial ovarian cancer is exceedingly rare. Ultrasonography and magnetic resonance imaging lack ionizing radiation and can be employed to evaluate disease extent. Tumor markers, including CA-125, AFP, LDH, inhibin-B, and even CEA and ßhCG may be informative. If required, chemotherapy can be administered following organogenesis during the second and third trimesters. Because platinum and other anti-neoplastic agents cross the placenta, chemotherapy should be withheld after 34 weeks to avoid neonatal myelosuppression. Bevacizumab, immune checkpoint inhibitors, and PARP inhibitors should be avoided throughout pregnancy. Although antenatal glucocorticoids to facilitate fetal pulmonary maturation and amniotic fluid index assessment can be considered, there is no d
- Published
- 2020
44. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Penson, Richard T, Huang, Helen, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, DiSaia, Philip J, Copeland, Larry J, Creasman, William T, Stehman, Frederick B, Brady, Mark F, Burger, Robert A, Thigpen, J Tate, Birrer, Michael J, Waggoner, Steven E, Moore, David H, Look, Katherine Y, Koh, Wui-Jin, Monk, Bradley J, Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Penson, Richard T, Huang, Helen, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, DiSaia, Philip J, Copeland, Larry J, Creasman, William T, Stehman, Frederick B, Brady, Mark F, Burger, Robert A, Thigpen, J Tate, Birrer, Michael J, Waggoner, Steven E, Moore, David H, Look, Katherine Y, Koh, Wui-Jin, and Monk, Bradley J
- Abstract
BackgroundOn Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of improved overall survival (OS) after the second interim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial. In this study, we report the prespecified final analysis of the primary objectives, OS and adverse events.MethodsIn this randomised, controlled, open-label, phase 3 trial, we recruited patients with metastatic, persistent, or recurrent cervical carcinoma from 81 centres in the USA, Canada, and Spain. Inclusion criteria included a GOG performance status score of 0 or 1; adequate renal, hepatic, and bone marrow function; adequately anticoagulated thromboembolism; a urine protein to creatinine ratio of less than 1; and measurable disease. Patients who had received chemotherapy for recurrence and those with non-healing wounds or active bleeding conditions were ineligible. We randomly allocated patients 1:1:1:1 (blocking used; block size of four) to intravenous chemotherapy of either cisplatin (50 mg/m2 on day 1 or 2) plus paclitaxel (135 mg/m2 or 175 mg/m2 on day 1) or topotecan (0·75 mg/m2 on days 1-3) plus paclitaxel (175 mg/m2 on day 1) with or without intravenous bevacizumab (15 mg/kg on day 1) in 21 day cycles until disease progression, unacceptable toxic effects, voluntary withdrawal by the patient, or complete response. We stratified randomisation by GOG performance status (0 vs 1), previous radiosensitising platinum-based chemotherapy, and disease status (recurrent or persistent vs metastatic). We gave treatment open label. Primary outcomes were OS (analysed in the intention-to-treat population) and adverse events (analysed in all patients who received treatment and submitted adverse event information), assessed at the second interim and final analysis by the masked Data and Safety Monitoring Board. The cutoff for final analysis was 450 patients with 346 deaths.
- Published
- 2017
45. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
- Author
-
Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Penson, Richard T, Huang, Helen, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, DiSaia, Philip J, Copeland, Larry J, Creasman, William T, Stehman, Frederick B, Brady, Mark F, Burger, Robert A, Thigpen, J Tate, Birrer, Michael J, Waggoner, Steven E, Moore, David H, Look, Katherine Y, Koh, Wui-Jin, Monk, Bradley J, Tewari, Krishnansu S, Tewari, Krishnansu S, Sill, Michael W, Penson, Richard T, Huang, Helen, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, DiSaia, Philip J, Copeland, Larry J, Creasman, William T, Stehman, Frederick B, Brady, Mark F, Burger, Robert A, Thigpen, J Tate, Birrer, Michael J, Waggoner, Steven E, Moore, David H, Look, Katherine Y, Koh, Wui-Jin, and Monk, Bradley J
- Abstract
BackgroundOn Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of improved overall survival (OS) after the second interim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial. In this study, we report the prespecified final analysis of the primary objectives, OS and adverse events.MethodsIn this randomised, controlled, open-label, phase 3 trial, we recruited patients with metastatic, persistent, or recurrent cervical carcinoma from 81 centres in the USA, Canada, and Spain. Inclusion criteria included a GOG performance status score of 0 or 1; adequate renal, hepatic, and bone marrow function; adequately anticoagulated thromboembolism; a urine protein to creatinine ratio of less than 1; and measurable disease. Patients who had received chemotherapy for recurrence and those with non-healing wounds or active bleeding conditions were ineligible. We randomly allocated patients 1:1:1:1 (blocking used; block size of four) to intravenous chemotherapy of either cisplatin (50 mg/m2 on day 1 or 2) plus paclitaxel (135 mg/m2 or 175 mg/m2 on day 1) or topotecan (0·75 mg/m2 on days 1-3) plus paclitaxel (175 mg/m2 on day 1) with or without intravenous bevacizumab (15 mg/kg on day 1) in 21 day cycles until disease progression, unacceptable toxic effects, voluntary withdrawal by the patient, or complete response. We stratified randomisation by GOG performance status (0 vs 1), previous radiosensitising platinum-based chemotherapy, and disease status (recurrent or persistent vs metastatic). We gave treatment open label. Primary outcomes were OS (analysed in the intention-to-treat population) and adverse events (analysed in all patients who received treatment and submitted adverse event information), assessed at the second interim and final analysis by the masked Data and Safety Monitoring Board. The cutoff for final analysis was 450 patients with 346 deaths.
- Published
- 2017
46. Cervical cancer in Tanzania: A systematic review of current challenges in six domains.
- Author
-
Runge, Ava S, Runge, Ava S, Bernstein, Megan E, Lucas, Alexa N, Tewari, Krishnansu S, Runge, Ava S, Runge, Ava S, Bernstein, Megan E, Lucas, Alexa N, and Tewari, Krishnansu S
- Abstract
Cervical cancer is the most common cancer in Tanzania. After excluding human immunodeficiency virus, lower respiratory infections, malaria, diarrheal diseases, and tuberculosis, cervical cancer kills more women than any other form of illness in the country. Unfortunately, Tanzania has a low doctor-to-patient ratio (1:50,000) and nearly 7000 women die each year from this disease. The clinical problem is further magnified by the country's lack of resources and prevailing poverty, sporadic cervical cancer screening, prevalence of high-risk oncogenic human papillomavirus subtypes, and relatively high rates of human immunodeficiency virus co-infection. In recent years, addressing the cervical cancer problem has become a priority for the Tanzanian government. In this systematic review of 39 peer-reviewed publications that appeared in the PubMed/MEDLINE (NCBI) database from 2013 to 2018, we synthesize the growing body of literature to capture current trends in Tanzania's evolving cervical cancer landscape. Six domains were identified, including risk factors, primary prevention, barriers to screening, treatment, healthcare worker education, and sustainability. In addition to traditional risk factors associated with sexual behavior, acetowhite changes observed during visual inspection of the cervix with acetic acid, lower education, rural setting, and HIV positivity also have a noteworthy clinical impact.
- Published
- 2019
47. Cervical cancer in Tanzania: A systematic review of current challenges in six domains.
- Author
-
Runge, Ava S, Runge, Ava S, Bernstein, Megan E, Lucas, Alexa N, Tewari, Krishnansu S, Runge, Ava S, Runge, Ava S, Bernstein, Megan E, Lucas, Alexa N, and Tewari, Krishnansu S
- Abstract
Cervical cancer is the most common cancer in Tanzania. After excluding human immunodeficiency virus, lower respiratory infections, malaria, diarrheal diseases, and tuberculosis, cervical cancer kills more women than any other form of illness in the country. Unfortunately, Tanzania has a low doctor-to-patient ratio (1:50,000) and nearly 7000 women die each year from this disease. The clinical problem is further magnified by the country's lack of resources and prevailing poverty, sporadic cervical cancer screening, prevalence of high-risk oncogenic human papillomavirus subtypes, and relatively high rates of human immunodeficiency virus co-infection. In recent years, addressing the cervical cancer problem has become a priority for the Tanzanian government. In this systematic review of 39 peer-reviewed publications that appeared in the PubMed/MEDLINE (NCBI) database from 2013 to 2018, we synthesize the growing body of literature to capture current trends in Tanzania's evolving cervical cancer landscape. Six domains were identified, including risk factors, primary prevention, barriers to screening, treatment, healthcare worker education, and sustainability. In addition to traditional risk factors associated with sexual behavior, acetowhite changes observed during visual inspection of the cervix with acetic acid, lower education, rural setting, and HIV positivity also have a noteworthy clinical impact.
- Published
- 2019
48. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.
- Author
-
Rose, Peter G, Rose, Peter G, Java, James J, Salani, Ritu, Geller, Melissa A, Secord, Angeles Alvarez, Tewari, Krishnansu S, Bender, David P, Mutch, David G, Friedlander, Michael L, Van Le, Linda, Method, Michael W, Hamilton, Chad A, Lee, Roger B, Wenham, Robert M, Guntupalli, Saketh R, Markman, Maurie, Muggia, Franco M, Armstrong, Deborah K, Bookman, Michael A, Burger, Robert A, Copeland, Larry J, Rose, Peter G, Rose, Peter G, Java, James J, Salani, Ritu, Geller, Melissa A, Secord, Angeles Alvarez, Tewari, Krishnansu S, Bender, David P, Mutch, David G, Friedlander, Michael L, Van Le, Linda, Method, Michael W, Hamilton, Chad A, Lee, Roger B, Wenham, Robert M, Guntupalli, Saketh R, Markman, Maurie, Muggia, Franco M, Armstrong, Deborah K, Bookman, Michael A, Burger, Robert A, and Copeland, Larry J
- Abstract
ObjectiveTo analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian-peritoneal-tubal carcinoma and to develop a nomogram to predict individual survival after recurrence.MethodsWe retrospectively analyzed patients treated in multicenter Gynecologic Oncology Group protocols for stage III and IV ovarian-peritoneal-tubal carcinoma who underwent primary debulking surgery, received chemotherapy with paclitaxel and a platinum compound, and subsequently developed recurrence. Prognostic factors affecting survival were identified and used to develop a nomogram, which was both internally and externally validated.ResultsThere were 4,739 patients included in this analysis, of whom, 84% had stage III and 16% had stage IV ovarian carcinoma. At a median follow-up of 88.8 months (95% CI 86.2-92.0 months), the vast majority of patients (89.4%) had died. The median survival after recurrence was 21.4 months (95% CI 20.5-21.9 months). Time to recurrence after initial chemotherapy, clear cell or mucinous histology, performance status, stage IV disease, and age were significant variables used to develop a nomogram for survival after recurrence, which had a concordance index of 0.67. The time to recurrence alone accounted for 85% of the prognostic information. Similar results were found for patients who underwent second look laparotomy and had a complete pathologic response or received intraperitoneal chemotherapy.ConclusionFor individuals with advanced-stage ovarian carcinoma who recur after standard first-line therapy, estimated survivals after recurrence are closely related to the time to recurrence after chemotherapy and prognostic variables can be used to predict subsequent survival.Clinical trial registrationClinialTrials.gov, NCT00002568, NCT00837993, NCT00002717, NCT01074398, and NCT00011986.
- Published
- 2019
49. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
- Author
-
Coleman, Robert L, Coleman, Robert L, Spirtos, Nick M, Enserro, Danielle, Herzog, Thomas J, Sabbatini, Paul, Armstrong, Deborah K, Kim, Jae-Weon, Park, Sang-Yoon, Kim, Byoung-Gie, Nam, Joo-Hyun, Fujiwara, Keiichi, Walker, Joan L, Casey, Ann C, Alvarez Secord, Angeles, Rubin, Steve, Chan, John K, DiSilvestro, Paul, Davidson, Susan A, Cohn, David E, Tewari, Krishnansu S, Basen-Engquist, Karen, Huang, Helen Q, Brady, Mark F, Mannel, Robert S, Coleman, Robert L, Coleman, Robert L, Spirtos, Nick M, Enserro, Danielle, Herzog, Thomas J, Sabbatini, Paul, Armstrong, Deborah K, Kim, Jae-Weon, Park, Sang-Yoon, Kim, Byoung-Gie, Nam, Joo-Hyun, Fujiwara, Keiichi, Walker, Joan L, Casey, Ann C, Alvarez Secord, Angeles, Rubin, Steve, Chan, John K, DiSilvestro, Paul, Davidson, Susan A, Cohn, David E, Tewari, Krishnansu S, Basen-Engquist, Karen, Huang, Helen Q, Brady, Mark F, and Mannel, Robert S
- Abstract
BackgroundSecondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation.MethodsWe randomly assigned patients with recurrent ovarian cancer who had received one previous therapy, had an interval during which no platinum-based chemotherapy was used (platinum-free interval) of 6 months or more, and had investigator-determined resectable disease (to no macroscopic residual disease) to undergo secondary surgical cytoreduction and then receive platinum-based chemotherapy or to receive platinum-based chemotherapy alone. Adjuvant chemotherapy (paclitaxel-carboplatin or gemcitabine-carboplatin) and use of bevacizumab were at the discretion of the investigator. The primary end point was overall survival.ResultsA total of 485 patients underwent randomization, 240 to secondary cytoreduction before chemotherapy and 245 to chemotherapy alone. The median follow-up was 48.1 months. Complete gross resection was achieved in 67% of the patients assigned to surgery who underwent the procedure. Platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance was administered to 84% of the patients overall and was equally distributed between the two groups. The hazard ratio for death (surgery vs. no surgery) was 1.29 (95% confidence interval [CI], 0.97 to 1.72; P = 0.08), which corresponded to a median overall survival of 50.6 months and 64.7 months, respectively. Adjustment for platinum-free interval and chemotherapy choice did not alter the effect. The hazard ratio for disease progression or death (surgery vs. no surgery) was 0.82 (95% CI, 0.66 to 1.01; median progression-free survival, 18.9 months and 16.2 months, respectively). Surgical morbidity at 30 days was 9%; 1 patient (0.4%) died from postoperative complications. Patient-reported quality of life decreased significantly after surgery but did not diffe
- Published
- 2019
50. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
- Author
-
Walker, Joan L, Walker, Joan L, Brady, Mark F, Wenzel, Lari, Fleming, Gini F, Huang, Helen Q, DiSilvestro, Paul A, Fujiwara, Keiichi, Alberts, David S, Zheng, Wenxin, Tewari, Krishnansu S, Cohn, David E, Powell, Matthew A, Van Le, Linda, Davidson, Susan A, Gray, Heidi J, Rose, Peter G, Aghajanian, Carol, Myers, Tashanna, Alvarez Secord, Angeles, Rubin, Stephen C, Mannel, Robert S, Walker, Joan L, Walker, Joan L, Brady, Mark F, Wenzel, Lari, Fleming, Gini F, Huang, Helen Q, DiSilvestro, Paul A, Fujiwara, Keiichi, Alberts, David S, Zheng, Wenxin, Tewari, Krishnansu S, Cohn, David E, Powell, Matthew A, Van Le, Linda, Davidson, Susan A, Gray, Heidi J, Rose, Peter G, Aghajanian, Carol, Myers, Tashanna, Alvarez Secord, Angeles, Rubin, Stephen C, and Mannel, Robert S
- Abstract
PurposeTo evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma.MethodsEligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m2 once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m2 over 3 hours day 1, IP cisplatin 75 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22.ResultsA total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9, 38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8 months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm.ConclusionCompared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.